News & Updates

The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.

In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.

A dietary pattern with high inflammatory potential contributes to an increased risk of nonalcoholic fatty liver disease (NAFLD), a recent study has shown.

The risk of colorectal cancer (CRC) is heightened in patients with serrated polyposis syndrome (SPS) and their first-degree relatives (FDRs), according to a study, which confirms findings of other reports. In addition, those with sessile serrated lesions (SSL) are at higher of prostate cancer.

Overweight or obese patients with nonalcoholic fatty liver disease (NAFLD) may gain health benefits from a low free sugar diet, results of a trial have shown. Such diet helps reduce hepatic steatosis and fibrosis, as well as improve glycaemic indices and lower concentrations of biomarkers of inflammation, triglycerides (TG), and total cholesterol (TC) levels.

Starting vedolizumab early after the diagnosis of ulcerative colitis (UC) appeared more effective than delaying it to after initiation of other UC treatments, according to the RALEE study.

Physical activity (PA) is associated with a lower prevalence of nonalcoholic fatty liver disease (NAFLD), with greater benefits for higher PA intensities, reveals a study. Better metabolic health, particularly lower waist circumference and insulin resistance, mediates this association.